ES2721781T3 - Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa - Google Patents

Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa Download PDF

Info

Publication number
ES2721781T3
ES2721781T3 ES16717470T ES16717470T ES2721781T3 ES 2721781 T3 ES2721781 T3 ES 2721781T3 ES 16717470 T ES16717470 T ES 16717470T ES 16717470 T ES16717470 T ES 16717470T ES 2721781 T3 ES2721781 T3 ES 2721781T3
Authority
ES
Spain
Prior art keywords
convertase
measure
factor
protease activity
complement pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16717470T
Other languages
English (en)
Inventor
Krista Johnson
Christen Forbes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2721781T3 publication Critical patent/ES2721781T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/537—Protease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para medir la actividad proteasa de C3 convertasa que comprende las etapas de: a. unir covalentemente biotina a C3b para producir C3b biotinilado (bio-C3b); b. unir C3b biotinilado a una proteína de unión a biotina inmovilizada sobre una fase sólida; c. incubar el C3b biotinilado inmovilizado, factor D y factor B en un tampón para formar una C3 convertasa; d. transferir C3 al tampón para escindir C3 con la convertasa para formar C3a y C3b; y e. medir la cantidad de C3a con un inmunoensayo, en donde cada uno de los componentes individuales, bio-C3b, factor B, factor D y C3 son sustancialmente homogéneos.
ES16717470T 2015-03-25 2016-03-28 Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa Active ES2721781T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138235P 2015-03-25 2015-03-25
PCT/IB2016/051750 WO2016151557A1 (en) 2015-03-25 2016-03-28 A method for measuring the protease activity of c5 convertase of the alternative complement pathway

Publications (1)

Publication Number Publication Date
ES2721781T3 true ES2721781T3 (es) 2019-08-05

Family

ID=55795010

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16717470T Active ES2721781T3 (es) 2015-03-25 2016-03-28 Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa

Country Status (5)

Country Link
US (2) US20180087087A1 (es)
EP (1) EP3274468B1 (es)
ES (1) ES2721781T3 (es)
TR (1) TR201904903T4 (es)
WO (1) WO2016151557A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190877A1 (en) * 2018-03-26 2019-10-03 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4582810A (en) 1983-09-30 1986-04-15 Becton, Dickinson And Company Immuno-agglutination particle suspensions
DE3640412A1 (de) 1986-11-26 1988-06-09 Boehringer Mannheim Gmbh Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6221657B1 (en) 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
DE19724787A1 (de) 1997-06-06 1998-12-10 Biotez Berlin Buch Gmbh Bioche Streptavidin/Avidin beschichtete Oberflächen
WO2003016470A2 (en) 2001-08-10 2003-02-27 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
WO2003023360A2 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Methods and apparatus for conducting multiple measurements on a sample
AU2003293562A1 (en) 2002-12-26 2004-07-22 Meso Scale Technologies, Llc Methods, compositions and kits for biomarker extraction
US7319525B2 (en) 2003-11-06 2008-01-15 Fortebio, Inc. Fiber-optic assay apparatus based on phase-shift interferometry
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
AU2009298708A1 (en) 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
WO2011085057A2 (en) 2010-01-06 2011-07-14 The Regents Of The University Of Colorado, A Body Corporate Methods for detecting insulin autoantibody
EP2824111B1 (en) 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies

Also Published As

Publication number Publication date
WO2016151557A1 (en) 2016-09-29
EP3274468B1 (en) 2019-02-20
TR201904903T4 (tr) 2019-05-21
US20230265481A1 (en) 2023-08-24
US20180087087A1 (en) 2018-03-29
EP3274468A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
CU20150023A7 (es) Anticuerpos anti-mcam y metodos de uso asociados
MX2018004988A (es) Moleculas de union que inhibe el crecimiento de cancer.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
MX2022007861A (es) Bibliotecas de polipeptidos modulares y metodos para elaborarlas y usarlas.
IL287035A (en) Anti-ige antibodies
HUE043421T2 (hu) IL-2R béta / közös gamma-lánc antitestek
EP3825404A4 (en) SINGLE-CHAIN ANTI-GPC3 ANTIBODY WITH CAR
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
AR092968A1 (es) Anticuerpos monoclonales y metodos de deteccion para enzimas que confieren resistencia a la fosfinotricina-n-acetil-transferasa
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
PE20190229A1 (es) Anticuerpos anti-fcrn
EP3470424C0 (en) ANTIBODY HEAVY CHAIN CONSTANT REGION SEQUENCE FOR ENHANCING AGONIST ANTIBODY ACTIVITY
BR112015022034A2 (pt) Camundongo, célula isolada, embrião de camundongo, hibridoma, uso de um camundongo, e, método para fabricar um anticorpo
MX351127B (es) Proteínas de unión al antígeno del receptor de oncostatina m.
EP3938721C0 (de) Kryostat
MA49250A (fr) Nouveaux anticorps anti-cd3
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2019009539A (es) Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).
MA55705A (fr) Anticorps bispécifiques
EP3758751A4 (en) MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
EP4150272C0 (en) CRYOSTAT